A Nature news feature has profiled a new wave of companies developing a different kind of gene therapy. Rather than cutting DNA, these therapies change the chemical markers that sit on it and switch genes on or off. The approach is called epigenetic editing.
The distinction matters. Standard CRISPR cuts the genetic code, which is precise but carries a risk of cuts in the wrong place. Epigenetic editing modifies the markers attached to DNA instead. Researchers quoted by Nature say this avoids off-target DNA mutations, and early work suggests the changes are reversible.
From concept to clinic
The field is now producing its first human data. Nature reports that one company presented results from an epigenetic-editing trial for facioscapulohumeral muscular dystrophy, an inherited muscle disorder. Another has begun dosing patients with an experimental therapy for chronic hepatitis B.
Earlier laboratory work points to broader uses. In one study, a single injection lowered a cholesterol-driving protein in monkeys by around 70 percent. The targets under investigation range from a rare muscle disease to high cholesterol.
Why it matters for Australia
Each advance like this widens what the genomics industry can treat. It also widens the gap between what is possible overseas and what Australian patients can access locally.
New classes of therapy do not fit neatly into existing systems. They raise fresh questions for regulators assessing safety, for committees judging value, and for the funding models that decide who pays. A system built around conventional medicines has to adapt to keep pace.
That work does not happen on its own. It needs a coordinated industry voice that can bring companies, regulators and government to the same table before these therapies arrive, not after. This is the space InGeNA works in.
Preparing the ground
The lesson from the first wave of gene editing is that approval and access are different problems. Australia can shorten the distance between them by building the regulatory and reimbursement pathways now, while the science is still maturing.
Epigenetic editing is early. Most of the work Nature describes is preclinical or in first trials. That is exactly why it is worth attention. The decisions that shape access are easier to get right before a therapy reaches the clinic.
Read the original feature in Nature.
Stay across genomics policy and access
New therapies reach Australian patients only when the pathways behind them work. The InGeNA newsletter tracks the policy, reimbursement and market access decisions that decide whether they do.
Subscribe to the InGeNA newsletter now for regular sector updates.